EU Commission, member states ‘deeply dissatisfied’ with AstraZeneca after revelation of delayed vaccine delivery
In a series of tweets late Friday, EU Commissioner for Health Stella Kyriakides said the delays had been revealed by representatives for the British-Swedish pharma firm earlier that day “compared to the forecast for the first quarter of this year.”
“The EU Commission and Member States expressed deep dissatisfaction with this,” she added.
We insisted on a precise delivery schedule on the basis of which Member States should be planning their vaccination programs, subject to the granting of a conditional marketing authorization.
EU regulators have not yet approved the vaccine, jointly developed by AstraZeneca and the UK’s Oxford University, but the bloc has pre-ordered up to 400 million doses, of which about 80 million were due to be delivered by March.
A senior EU official told Reuters that the reduced figure means a drop of 60 percent in the delivery for that period, to 31 million doses.Also on rt.com WHO vaccine chief says 'crushing transmission' of Covid-19 is vital to avoid further mutations amid global vaccine roll-out
The European Medicines Agency’s decision on approving the conditional marketing authorization of the vaccine could be made before the end of this month. Clinical trials have reported it has a 94.5 percent efficacy against Covid-19.
The AstraZeneca inoculation is relatively easier to handle than some others given it can be stored at 2-8 degrees Celsius, compared to Sputnik V’s -18C, Moderna’s -20C, and Pfizer’s -70C.
News of the AstraZenca hiccup comes after the EU said it was seeking "clarification" from Pfizer over further reductions to its deliveries, having previously announced a fall in deliveries as it works to upgrade manufacturing capacity in Belgium.
Think your friends would be interested? Share this story!